USPTO 2015–2025 USPTO PatentsView US Corporation

Emplase Medical Technologies, Llc

USPTO PatentsView assignee record - 7 granted patents across 3 technology areas, active 2024–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE).

7
Total patents granted
3
CPC technology areas
20.3
Avg claims per patent
-
5-year filing velocity

The verdict

Emplase holds 7 US patents across 3 technology areas, rank #35,140 of 50,000 tracked assignees.

#35,140
of 50,000 US assignees by volume
Top 23%
by Innovation Score (45.5/100)
20.3
avg claims per patent

Portfolio overview

Emplase Medical Technologies, Llc has been granted 7 US utility patents between 2024 and 2025, placing Emplase Medical Technologies, Llc at rank #35,140 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.3 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a US Corporation, Emplase Medical Technologies, Llc is one of the more focused assignees in the PatentsView dataset. By volume, Emplase sits between Emisense Technologies, Llc (7 patents, rank #35,136) and Endostream Medical Ltd. (7 patents, rank #35,144) - the closest US assignees by grant volume. The composite Innovation Score of 45.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Historical data spans 2024 through 2025, with 7 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Emplase Medical Technologies, Llc's 20.3 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Emplase Medical Technologies, Llc against peers pursuing similar technology classes.

Who files at Emplase's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Emplase holds 7 patents at rank #35,140, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Emplase

By rank, the assignees closest to #35,140 in granted patent volume.

Leaders in A61F (Filters Implantable INTO Blood Vessels)

Other assignees with the most granted patents in Emplase's primary technology class.

Emplase's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

45 Top 23% higher than 77% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

2.533.544.5 20242025 4
USPTO utility patent grants by year · 2024–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2024–2019 baseline. Full figures in the table below.

View data table
Emplase Medical Technologies, Llc patent grants by year, 2015–2025
Year Patents Granted Share of Period
2024 3 42.9%
2025 4 57.1%

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Complex

Where it ranks

Overall rank by patents

#35,140

Across all tracked assignees

Innovation Score

45.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Emplase Medical Technologies, Llc hold?
Emplase Medical Technologies, Llc holds 7 US granted patents filed between 2024 and 2025, spanning 3 technology areas.
What is Emplase Medical Technologies, Llc's Innovation Score?
Emplase Medical Technologies, Llc has an Innovation Score of 45.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Emplase Medical Technologies, Llc focus on?
Emplase Medical Technologies, Llc's top technology area is A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRS) with 7 patents. The company has filed patents in 3 CPC subclasses total.
Is Emplase Medical Technologies, Llc's patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Emplase Medical Technologies, Llc.
What does claim depth mean for Emplase Medical Technologies, Llc's patents?
Emplase Medical Technologies, Llc's patents average 20.3 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Emplase Medical Technologies, Llc patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Emplase's 7 grants land it in the top 23% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Emplase ranks #35,140 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61F - see who else leads that technology area. A61F leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.